Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA)
| Autor: | Ma Luz Lamelas, Juan C. Rodríguez, Maite Allende, Francisco J. Vizoso, Antonio Fueyo, José C. Fernández, Lucia García, Julio Vázquez, María D. Corte, Juan A. Rodil, García-Muñiz Jl, Miguel Bongera, Luis O. González |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Cancer Research
medicine.medical_specialty Receptor ErbB-2 Estrogen receptor Breast Neoplasms Enzyme-Linked Immunosorbent Assay Biology Disease-Free Survival Andrology Cytosol Breast cancer Statistical significance Internal medicine medicine Humans Clinical significance Receptor Hematology Carcinoma Ductal Breast General Medicine Middle Aged medicine.disease Immunohistochemistry Survival Analysis Gene Expression Regulation Neoplastic Endocrinology Oncology Quartile Hormonal therapy Female |
| Zdroj: | Journal of Cancer Research and Clinical Oncology. 131:701-714 |
| ISSN: | 1432-1335 0171-5216 |
| Popis: | Purpose: Retrospective analysis to assess the prognostic and predictive value of HER-2/ neu expression in breast tumors, quantified by enzyme immunoassay (ELISA).Methods: Quantification of HER-2/neu was performed on cytosolic extracts from 914 cases of primary invasive breast carcinomas. Relapse-free and overall survival data were available from 889 patients. The prognostic value of HER-2/neu levels was assessed considering them as a continuous, dichotomic or quartile variable.Results: Cytosolic HER-2/neu levels ranged widely in breast carcinomas (median: 746.5 NHU/mg; range: 2.8–80,000 NHU/mg protein). HER-2/neu protein levels were significantly higher in either moderately or poorly differentiated tumors, as well as in those showing a ductal histological type, aneuploidy or a high S-phase fraction. There was a significant and positive association between cytosolic and membranous HER-2/neu levels (n=162, r sub S=0.53; P Q 3), we observed that patients with either low HER-2/ neu levels (≤ Q 1) or high HER-2/neu levels (> Q 3) had shorter both relapse-free survival and overall survival curves than those patients with intermediate HER-2/neu levels. On the other hand, high HER-2/neu levels predicted a poor response to adjuvant chemotherapy but not to adjuvant hormonal therapy with tamoxifen.Conclusions: The results of the present investigation indicate that by quantitatively determining the content of HER-2/neu oncoprotein, groups of high-risk breast cancer patients could be identified, for a more effective clinical management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink